[go: up one dir, main page]

TW200516077A - Powder formulation containing the CGRP antagonist 1-[n2-[3,5-dibromo-n-[[4-(3,4-dihydro-2(1h)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-d-tyrosyl]-l-lysyl]-4-(4-pyridinyl)-piperazin, process for preparing and the use thereof as inhalation powder - Google Patents

Powder formulation containing the CGRP antagonist 1-[n2-[3,5-dibromo-n-[[4-(3,4-dihydro-2(1h)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-d-tyrosyl]-l-lysyl]-4-(4-pyridinyl)-piperazin, process for preparing and the use thereof as inhalation powder

Info

Publication number
TW200516077A
TW200516077A TW093124725A TW93124725A TW200516077A TW 200516077 A TW200516077 A TW 200516077A TW 093124725 A TW093124725 A TW 093124725A TW 93124725 A TW93124725 A TW 93124725A TW 200516077 A TW200516077 A TW 200516077A
Authority
TW
Taiwan
Prior art keywords
preparing
powder
oxoquinazolin
tyrosyl
lysyl
Prior art date
Application number
TW093124725A
Other languages
English (en)
Inventor
Michael Trunk
Claudius Weiler
Christel Schmelzer
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of TW200516077A publication Critical patent/TW200516077A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW093124725A 2003-08-18 2004-08-17 Powder formulation containing the CGRP antagonist 1-[n2-[3,5-dibromo-n-[[4-(3,4-dihydro-2(1h)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-d-tyrosyl]-l-lysyl]-4-(4-pyridinyl)-piperazin, process for preparing and the use thereof as inhalation powder TW200516077A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10338403A DE10338403A1 (de) 2003-08-18 2003-08-18 Pulverformulierung, enthaltend den CGRP-Antagonisten 1-[N2-[3,5-Dibrom-N-[[4-(3,4-dihydro-2(1H)-oxochinazolin-3-yl]-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyrindinyl)-piperazin, Verfahren zu dessen Herstellung sowie dessen Verwendung als Inhalativum

Publications (1)

Publication Number Publication Date
TW200516077A true TW200516077A (en) 2005-05-16

Family

ID=34201782

Family Applications (1)

Application Number Title Priority Date Filing Date
TW093124725A TW200516077A (en) 2003-08-18 2004-08-17 Powder formulation containing the CGRP antagonist 1-[n2-[3,5-dibromo-n-[[4-(3,4-dihydro-2(1h)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-d-tyrosyl]-l-lysyl]-4-(4-pyridinyl)-piperazin, process for preparing and the use thereof as inhalation powder

Country Status (7)

Country Link
EP (1) EP1660046A1 (zh)
JP (1) JP2007502792A (zh)
AR (1) AR045461A1 (zh)
CA (1) CA2536053A1 (zh)
DE (1) DE10338403A1 (zh)
TW (1) TW200516077A (zh)
WO (1) WO2005018614A1 (zh)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10338407A1 (de) * 2003-08-18 2005-03-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Inhalationspulver enthaltend den CGRP-Antagonisten 1-[N2-[3,5-Dibrom-N-[[4-(3,4-dihydro-2(1H)-oxochinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazin
DE10338399A1 (de) * 2003-08-18 2005-03-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Mikropartikel, enthaltend den CGRP-Antagonisten 1-[N2-[3,5-Dibrom-N-[[4-(3,4-dihydro-2(1H)-oxochinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-Iysyl]-4-(4-pyridinyl)-piperazin, Verfahren zu deren Herstellung sowie deren Verwendung als Inhalaltionspulver
DE10338402A1 (de) * 2003-08-18 2005-03-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Sprühgetrocknetes, amorphes BIBN 4096, Verfahren zu dessen Herstellung sowie dessen Verwendung als Inhalativum
GB0613925D0 (en) * 2006-07-13 2006-08-23 Unilever Plc Improvements relating to nanodispersions

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1242211A (en) * 1967-08-08 1971-08-11 Fisons Pharmaceuticals Ltd Pharmaceutical composition
MA25590A1 (fr) * 1998-09-14 2002-12-31 Inhale Therapeutic Syst Agent actif de delivraison de poudre seche
DE10139410A1 (de) * 2001-08-17 2003-02-27 Boehringer Ingelheim Pharma Verwendung von BIBN4096 in Kombination mit anderen Arzneistoffen gegen Migräne für die Behandlung von Migräne
DE10206770A1 (de) * 2002-02-19 2003-08-28 Boehringer Ingelheim Pharma Verfahren zur Herstellung eines Pulverinhalativums enthaltend ein Salz des CGRP-Antagonisten BIBN4096
DE10207026A1 (de) * 2002-02-20 2003-08-28 Boehringer Ingelheim Kg Pulverinhalativum, enthaltend den CGRP-Antagonisten BIBN4096 und Verfahren zu dessen Herstellung

Also Published As

Publication number Publication date
EP1660046A1 (de) 2006-05-31
DE10338403A1 (de) 2005-03-17
CA2536053A1 (en) 2005-03-03
JP2007502792A (ja) 2007-02-15
WO2005018614A1 (de) 2005-03-03
AR045461A1 (es) 2005-10-26

Similar Documents

Publication Publication Date Title
WO2005018603A3 (de) Sprühgetrocknetes, amorphes bibn 4096, verfahren zu dessen herstellung sowie dessen verwendung als inhalativum
UA91401C2 (en) 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(n,n-dimethylamino)-1-oxo-2-butene-1-yl]amino}-7-((s)-tetrahydrofurane-3-yloxy)-quinazoline maleate, production method and uses thereof
MX2010006238A (es) Formulaciones del acido 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5 -il)ciclopropancarboxamido)-3-metilpiridin-2-il)benzoico.
MY131890A (en) Piperidine compounds
MXPA02011311A (es) Composicion novedosa.
NZ593593A (en) Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
WO2002085909A8 (en) 9-deazaguanine derivatives as inhibitors of gsk-3
EP1827468A4 (en) LEUPROLID ACETATE AND ACETYLCHOLINESTERASE INHIBITORS OR NMDA RECEPTOR ANTAGONISTS FOR THE TREATMENT OF ALZHEIMER DISEASE
DE60120936D1 (de) Behandlung von atemerkrankungen
WO2002015662A3 (en) Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic acetylcholine receptor antagonists
WO2002032893A3 (en) Piperidine compounds as anti-allergic
WO2008114275A3 (en) Anthranilic acid derivatives as anticancer agents and process for the preparation thereof
NO20060020L (no) 3-fluorpiperidiner som NMDA/NR2B-antagonister
PE20050897A1 (es) Nuevos antagonistas del receptor muscarinico m3 de acetilcolina
WO2003087049A3 (de) Arzneimittelkombinationen enthaltend heterocyclische verbindungen und ein neues anticholinergikum
PE20030931A1 (es) Procedimiento para la preparacion de un producto de inhalacion en polvo que contiene una sal del antagonista de cgrp, bibn4096
WO2005011594A3 (en) Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a tyrosine kinase inhibitor, delta opioid receptor antagonist, neurokinin receptor antagonist, or vcam inhibitor for treatment of asthma or chronic obstructive pulmonary disease
GR3036639T3 (en) 5-(4-subst.-piperidinyl-1)-3-aryl-pentanoic acid derivatives as tachykinin receptor antagonist
TW200516077A (en) Powder formulation containing the CGRP antagonist 1-[n2-[3,5-dibromo-n-[[4-(3,4-dihydro-2(1h)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-d-tyrosyl]-l-lysyl]-4-(4-pyridinyl)-piperazin, process for preparing and the use thereof as inhalation powder
HUP0401484A2 (hu) BIBN4096 alkalmazása kombinációban más migrénellenes szerekkel migrén kezelésére és a kombinációt tartalmazó gyógyszerkészítmények
SG11201810138XA (en) Beta-hairpin peptidomimetic with elastase inhibitory activity and aerosol dosage forms thereof
MXPA03003785A (es) Suspension de una proteina epi-hne, proceso de preparacion de la misma, aerosol en polvo seco derivado de la misma, composiciones farmaceuticas conteniendo dicha suspension o aerosol y sus usos.
MX2009003974A (es) N-(2-hidroxietil)-n-metil-4-(quinolin-8-il(1-(tiazol-4-ilmetil)pi peridin-4-ilideno)metil)benzamida, el proceso para su sintesis, asi como su uso para el tratamiento del dolor, la ansiedad y la depresion.
CA2563687A1 (en) Use of a cgrp-antagonist combined with a serotonin-reuptake inhibitor in order to treat migraines
SG137859A1 (en) Method for producing tiotropium salts, tiotropium salts and pharmaceutical formulations, containing the same